HLS Therapeutics (TSE:HLS) Shares Down 0.2% - Should You Sell?

Key Points

• Minimal price change but extremely low trading activity: Shares fell 0.2% to C$4.39 while volume was just 223 shares—about 98% below the average session volume, indicating very light trading.
• Company is reporting losses: HLS posted C($0.05) EPS last quarter, has a negative net margin (-22.34%) and ROE (-19.40%), and analysts forecast about C($0.12) EPS for the current fiscal year.
• Modest market cap with leverage and weak trend: Market cap is C$137.3M, debt-to-equity is 80.79, liquidity ratios are around 1.1, and the share price sits below its 200-day moving average (C$4.89).

HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s stock price traded down 0.2% during trading on Monday . The company traded as low as C$4.39 and last traded at C$4.39. 223 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 9,278 shares. The stock had previously closed at C$4.40.

HLS Therapeutics Stock Performance

The company has a market cap of C$137.29 million, a P/E ratio of -11.26 and a beta of 0.34. The company has a quick ratio of 1.01, a current ratio of 1.11 and a debt-to-equity ratio of 80.79. The stock's 50-day moving average price is C$4.45 and its 200 day moving average price is C$4.89.

HLS Therapeutics (TSE:HLS - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported C($0.05) EPS for the quarter. The firm had revenue of C$20.06 million during the quarter. HLS Therapeutics had a negative net margin of 22.34% and a negative return on equity of 19.40%. As a group, research analysts expect that HLS Therapeutics Inc. will post -0.12 EPS for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.